The Ministry of Health of the Russian Federation has registered Myorizon, which is a solution for intravenous and intramuscular injection, 100 mg / ml+2.5 mg/ml produced by Moscow Endocrine Plant FSUE.
Registration certificate No. LP-006727, registration date is 27th of January of 2021.
Myorizon, solution for intravenous and intramuscular injections (INN tolperizon+[lidocaine]) is a centrally acting muscle relaxant which belongs to pharmacotherapeutic group. The drug is used for the symptomatic treatment of spasticity caused by stroke, myofascial pain syndrome of a moderate and severe degree in adults (including muscle spasm in dorsopathies).
The company plans to release the first commercial batch in the first quarter of 2021.
Comment type is not specified in the component properties.